Social media

Andrew Roche, Senior Director of Scientific Affairs, will be speaking at the Biomarkers & Precision Medicine conference on 1 October at 2:50 PM. In his session, “Key considerations for high-quality data generation in g...

Discover how ICON’s #drug development experts, using advanced modelling and simulation, assessed the clinical hypothesis and identified opportunities to simplify the development path. https://ow.ly/COWp50WNlMe #ICONEx...

Discover how ICON’s #drug development experts, using advanced modelling and simulation, assessed the clinical hypothesis and identified opportunities to simplify the development path. https://ow.ly/Et7850WNlM9 #ICONEx...

ICON's new CEO speaks to BioXconomy on industry challenges - and opportunities - ahead. Discover more: https://ow.ly/zY9y50WXGUW

ICON's new CEO speaks to BioXconomy on industry challenges - and opportunities - ahead. Discover more: https://ow.ly/S6I650WXGUX

ICON’s Victoria DeVeaugh-Geiss, Director of Clinical Operations, will share insights on holistic risk management in clinical trials and explore how evolving RBQM and RBDM strategies can drive cross-functional success. ht...

ICON’s Victoria DeVeaugh-Geiss, Director of Clinical Operations, will share insights on holistic risk management in clinical trials and explore how evolving RBQM and RBDM strategies can drive cross-functional success. ht...

Accelerating access to innovative therapies is more than a regulatory ambition—it’s a strategic imperative for sponsors navigating global approvals. From FDA’s Project Orbis to EMA’s PRIME and WHO’s Collaborative Registr...

Faster access to life-saving therapies is within reach. Global regulators are working together to speed approvals for oncology and rare disease treatments—but navigating these pathways takes foresight and expertise. Ou...

The #EASD2025 Annual Meeting is now underway at VIECON in Vienna. Adam Amory, Valerio Adinolfi, and Danica Kićevac are welcoming attendees at booth #E1.02 in Hall B of the exhibition area. We invite you to stop by to dis...

Meaningful outcomes in obesity trials go beyond the scale. By integrating COAs and DHTs, sponsors can capture real-world, patient-centered insights that improve both regulatory alignment and trial value. Join us on Oct...

Meaningful outcomes in obesity trials go beyond the scale. By integrating COAs and DHTs, sponsors can capture real-world, patient-centered insights that improve both regulatory alignment and trial value. Join us on Oct...